Allo-SCT is an established therapy primarily used to eradicate various types of hematological malignancy. However, defects in cellular and humoral immunity persist for months (even years) after allo-SCT. Successful reconstitution of the immune system is important for decreasing the complications of allo-SCT, such as infections and GVHD. Thus, identification of the risk factors for hypogammaglobulinemia will help in improving the outcomes of patients undergoing allo-SCT. However, to the best of our knowledge, only one large-scale study has explored the risk factors for hypogammaglobulinemia in adults. 1 The authors of that study found that acute GVHD (aGVHD), younger patients, lack of treatment with anti-thymocyte globulin (ATG), female donor to male recipient and treatment with CsA and MTX as prophylaxis against aGVHD were associated significantly with an increased risk for hypogammaglobulinemia after allo-SCT. However, that study did not involve newly developed procedures such as cord blood transplantation (CBT) or analyses of mycophenolate mofetil (MMF) usage as prophylaxis for GVHD. In a recent study of 185 pediatric patients undergoing allo-SCT, the risk factors identified for hypogammaglobulinemia were younger age, lower pretransplant IgG level, malignant disease, use of unrelated donor stem cell source and development of aGVHD. 2 We retrospectively investigated the risk factors for hypogammaglobulinemia in adult patients who underwent allo-SCT within our department between January 2001 and June 2012. This study was approved by the ethics committee of Kyoto University (E1714). These subjects survived ⩾28 days, and their Ig levels were measured before conditioning regimens and at least twice after allo-SCT. We assessed 299 cases of allo-SCT in 278 patients. Patient characteristics and allo-SCT procedures are summarized in Table 1 . Patients with multiple myeloma were excluded. Patients were divided into 'high-risk' and 'standard-risk' groups according to transplantation risk. 3 Disease status at allo-SCT was divided into 'controlled' and 'progressive' disease. 4 With respect to conditioning regimens, the definitions of myeloablative conditioning and reduced-intensity conditioning (RIC) were consistent with those of the RIC regimen workshop. 5 The prophylaxis of aGVHD comprised a calcineurin inhibitor (CsA or FK506) plus short-term MTX, 6 MMF (30 mg/kg/day, orally from day 0 until day 30), or both. ATG was not used in any case. Grade 2-4 aGVHD and extensive chronic GVHD (cGVHD) were treated with corticosteroids. Serum IgG levels were measured before conditioning regimens, at 2 weeks, 1, 3, 6 and 9 months and 1 and 3 years after allo-SCT. Once relapse was diagnosed, subsequent data on IgG levels were excluded from the study. IgG levels were additionally measured as clinically indicated. Hypogammaglobulinemia was defined as serum IgG level o 400 mg/dL, and patients whose IgG level was o 400 mg/ dL at least once were included in the hypogammaglobulinemia group. Patients with hypogammaglobulinemia or other conditions (for example, severe infection) received i.v. Ig replacement therapy according to the decision of the attending physician. Serum IgG levels after allo-SCT were compared with those before conditioning regimens using unpaired t tests. Univariate analyses of the cumulative incidence of hypogammaglobulinemia were undertaken using Kaplan-Meier methods considering relapse and TRM as a censor. Patients with GVHD only after the diagnosis of hypogammaglobulinemia were included in the non-GVHD group in this analysis. Factors with Po 0.1 and occurrence of GVHD were subjected to multivariate analyses using Cox proportional hazard models. Statistical analyses were performed using R ver 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria). The alpha level of all tests or the P-value was set at 0.05.
Hypogammaglobulinemia was observed in 63 patients at 5-2077 (median, 89) days after allo-SCT. The cumulative incidence of hypogammaglobulinemia 1 or 3 years after allo-SCT was 24.1% or 27.1% (95% confidence interval, 18.2%-29.5% or 20.7%-33.1%), respectively. More than 88% of the patients in the hypogammaglobulinemia group fulfilled the criteria for hypogammaglobulinemia within 1 year after allo-SCT. Serum IgG levels decreased significantly as early as 2 weeks after allo-SCT compared with preconditioning levels (mean ± s.e., 963.1 ± 28.0 mg/dL vs 810.5 ± 24.9 mg/dL, Po 0.01). IgG levels were lowest at 6 months (757.6 ± 39.9 mg/dL, P o0.01) and recovered to the preconditioning level 1 year after allo-SCT (958.8 ± 52.4 mg/dL, P = 0.99).
Next, we explored the risk factors for hypogammaglobulinemia after allo-SCT. Univariate analyses revealed a significantly higher incidence of hypogammaglobulinemia in patients with lymphoid malignancies (particularly with rituximab treatment), high-risk SCT, progressive disease, history of allo-SCT, HLA mismatch, MMF usage, low pre-SCT IgG levels (o 800 mg/dL) and grade 2-4 aGVHD ( Abbreviations: AA = aplastic anemia; aGVHD = acute GVHD; ATL = adult T-cell leukemia; CB = cord blood; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; ML = malignant lymphoma; MMF = mycophenolate mofetil; RIST = reduced-intensity SCT; RTX = rituximab therapy. malignancies (hazard ratio (HR) = 2.05, P = 0.02), history of allo-SCT (HR = 2.94, P o 0.01), MMF usage (HR = 2.55, P o0.01), low pre-SCT IgG levels (HR = 1.81, P = 0.04) and grade 2-4 aGVHD (HR = 2.15, P = 0.01) were significant risk factors for hypogammaglobulinemia (Table 2) .
Most risk factors for hypogammaglobulinemia in our study were associated with delayed recovery of B-cell function after allo-SCT. In patients with lymphoid malignancies, lymphocyte function is often suppressed even before chemotherapy, and IgG levels are usually lower than in those with other hematological malignancies. 7 Use of rituximab for B-cell lymphomas also reduces IgG levels. 7 The contribution of MMF to hypogammaglobulinemia after allo-SCT was a noticeable finding in the present study. Mycophenolic acid (an active and hydrolyzed form of MMF) can inhibit the synthesis of nucleic acids by suppressing the activity of inosine-5′-monophosphate dehydrogenase, and prevent the activation of B cells and T cells. 8 The potency of inhibition of Ab production is stronger than that of other immunosuppressive agents in solid-organ transplantation. 9 We are the first to demonstrate the relevance of the use of MMF to hypogammaglobulinemia after allo-SCT. Moreover, CBT was not identified as a significant risk factor for hypogammaglobulinemia in our study. This result is consistent with a recent report in which the number of circulating B cells was significantly elevated in CBT patients compared with those receiving other sources. 10 In summary, we identified significant risk factors for hypogammaglobulinemia after allo-SCT in 278 patients undergoing 299 transplantations. Our finding is valuable, because close monitoring of serum IgG levels in high-risk patients should allow for effective therapeutic interventions, including i.v. Ig replacement therapy and preemptive therapy for infection, resulting in better outcomes. Notably, a recent study demonstrated that i.v. Ig significantly reduced the incidence and associated mortality of GVHD, a risk factor for hypogammaglobulinemia, in a mouse model. 11 Finally, our study had limitations: a heterogeneous group of patients was assessed and it was a retrospective single-center study over a long time period. Large-scale prospective studies are needed to substantiate the results of this retrospective analysis. Abbreviations: aGVHD = acute GVHD; CB = cord blood; cGVHD = chronic GVHD; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; RIST = reduced-intensity SCT; RTX = rituximab therapy. *Indicates statistical significance (Po 0.05).
